Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey

Clin Infect Dis. 2021 Nov 2;73(9):e3120-e3123. doi: 10.1093/cid/ciaa1804.

Abstract

We compared severe acute respiratory syndrome coronavirus 2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April and May 2020 and found these 2 estimates to be similar (4.94% vs 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence.

Keywords: convenience sampling; coronavirus disease 2019 (COVID-19); seroprevalence; severe acute respiratory syndrome–related coronavirus 2 (SARS-CoV-2).

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Viral
  • COVID-19*
  • Humans
  • Laboratories
  • SARS-CoV-2*
  • Seroepidemiologic Studies
  • Surveys and Questionnaires

Substances

  • Antibodies, Viral

Grants and funding